c-MET expression in primary and liver metastases in uveal melanoma

F. Gardner(Florida Cancer Specialists & Research Institute), Richard W. Joseph(Daiichi Sankyo (United States)), Daniel Serie, Svetomir N. Markovic(Mayo Clinic in Arizona), Kevin J. Wu(Mayo Clinic), José S. Pulido(Wills Eye Hospital), Diva R. Salomão(Mayo Clinic in Arizona)

Melanoma Research

September 11, 2014

10.1097/cmr.0000000000000118

Cited by 40

Related Papers

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

|Nature Medicine|2002|5.1k

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|3.7k

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

|New England Journal of Medicine|2013|3.4k

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|2.2k

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

|The Lancet|2014|1.8k